Zenagamtide clinical trials
Also written NNC0487-0111.
How each study uses zenagamtide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zenagamtide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2026 (25); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 25 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 30 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test zenagamtide.
- Nov 2027Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesPhase 1 · Novo Nordisk A/S
Studies
Open first, then newest update. How each study uses zenagamtide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 30
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothNot yet recruitingPhase 3Novo Nordisk A/SNCT07931547Written as Zenagamtide
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNot yet recruitingPhase 3Novo Nordisk A/SNCT07931495Written as Zenagamtide
- A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNot yet recruitingPhase 3Novo Nordisk A/SNCT07931599Written as Zenagamtide
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNot yet recruitingPhase 3Novo Nordisk A/SNCT07931573Written as Zenagamtide
- A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver FunctionRecruitingPhase 1Novo Nordisk A/SNCT07587710Written as NNC0487-0111
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07855133Written as Zenagamtide
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07868354Written as Zenagamtide
- AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaRecruitingPhase 3Novo Nordisk A/SNCT07571109Written as NNC0487-0111
- A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07815067Written as Zenagamtide injection
- A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNot yet recruitingPhase 3Novo Nordisk A/SNCT07861100Written as Zenagamtide
- A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or PlaceboRecruitingPhase 1Novo Nordisk A/SNCT07757087Written as NNC0487-0111
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideRecruitingPhase 3Novo Nordisk A/SNCT07668414Written as Zenagamtide
- AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07720271Written as zenagamtide
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07339423Written as NNC0487-0111
- AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07822061Written as NNC0487-0111
- AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaRecruitingPhase 3Novo Nordisk A/SNCT07571005Written as NNC0487-0111
- AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsRecruitingPhase 3Novo Nordisk A/SNCT07797335Written as Zenagamtide
- AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNot yet recruitingPhase 3Novo Nordisk A/SNCT07668401Written as Zenagamtide
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityRecruitingPhase 3Novo Nordisk A/SNCT07567001Written as NNC0487-0111
- AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainRecruitingPhase 3Novo Nordisk A/SNCT07509307Written as NNC0487-0111
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered4
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNov 12, 2026NCT07931495
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothNov 12, 2026NCT07931547
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNov 12, 2026NCT07931573
- A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNov 12, 2026NCT07931599
Codes
What other systems call zenagamtide · ClinicalTrials.gg INT017962
- UNII (FDA) T2EA5S9XJ5ZENAGAMTIDEOne source FDA
- NCI Thesaurus C224807ZenagamtideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T2EA5S9XJ5 | ZENAGAMTIDE | One source FDA |
| NCI Thesaurus | C224807 | Zenagamtide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.